Answers are grounded in this paper and cite their sources.
Objectives: to analyze Brazilian evidence on the clinical benefits and quality-of-life impacts associated with FreeStyle Libre, considering recurring costs, sensor replacement, and barriers to access and education. Methods: an integrative literature review was conducted, complemented by official Brazilian documents. National studies addressing glycemic control, quality of life, diabetes education, costs, cost-effectiveness, budget impact, and incorporation into the Brazilian Unified Health System (SUS) were considered. Results: Brazilian real-world data indicate an association between more frequent use and better glycemic indicators. National studies also report favorable results in selected quality-of-life domains and suggest that diabetes education may enhance the use of the technology. However, the evidence has methodological limitations, and economic assessments indicate relevant recurring costs. CONITEC recommended against incorporating the technology into the SUS, with the decision formalized in 2025. Conclusions: FreeStyle Libre has potential clinical benefits and may improve the monitoring experience, but continued use is conditioned by costs, access, diabetes education, and sustainability.
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: